EUVIMEDEUVIMED entdecken
Crossref

Targeting JAK2 : Genetic and Pharmacological Inhibition Attenuates Immune‐Mediated Liver Injury by Suppressing Proinflammatory Macrophage

Xinlu Li, Xinxin Liu, Meijiang Zhou, Chenxi Yang, Jun Chen, Shunping Lin, Quan Gong, Zachary Braunstein, Yingying Wei, Xiaoquan Rao, Jixin Zhong

The FASEB Journal · 2026

DOI: 10.1096/fj.202504763rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Xinlu Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Immunology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and…. Hauptthemen laut MEDLINE: Janus Kinase 2, Macrophages, Sulfonamides, Azetidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: | Natural Science Foundation of Hubei Province (), MOST | National Natural Science Foundation of China (NSFC), MOST | National Key Research and Development Program of China (NKPs).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective therapeutic targets for immune‐mediated liver injury remain insufficient, necessitating the urgent development of novel therapeutic agents. Baricitinib is a selective Janus kinase (JAK) 1/2 inhibitor that shows promise in autoimmune diseases such as rheumatoid arthritis. However, its efficacy in immune‐mediated liver injury has not been fully elucidated. In this study, we found that JAK2 inhibitors fedratinib and baricitinib significantly mitigated liver damage, as evidenced by reduced serum transaminase levels, diminished histopathological injury, and suppressed inflammatory responses in concanavalin A (ConA)‐induced liver injury, a classic animal model of immune‐mediated liver injury. Mechanistic studies revealed that baricitinib's protective effects were mediated through JAK2 inhibition in macrophages. Myeloid‐specific JAK2 knockout mice exhibited blunted activation of macrophages and CD4 + T cells, conferring resistance to immune‐mediated liver injury induction. In vitro, macrophages isolated from baricitinib‐treated or JAK2‐deficient mice displayed less mature and activated phenotypes as evidenced by lower expressions of major histocompatibility complex class II (MHC‐II), inflammatory marker Ly6C, inflammatory cytokine production, and higher phagocytic capacity, which subsequently resulted in lower levels of CD4 + T cell activation. These findings collectively underscore baricitinib's therapeutic potential in modulating immune responses and restoring hepatic homeostasis in immune‐mediated liver injury, positioning it as a promising therapeutic candidate for this challenging condition. Further clinical validation is warranted to translate these preclinical insights into patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2MacrophagesSulfonamidesAzetidinesChemical and Drug Induced Liver InjuryInflammationAnimalsMicePyrazolesPurinesMice, KnockoutBenzenesulfonamidesMice, Inbred C57BLMaleConcanavalin ALiverCD4-Positive T-LymphocytesPyrrolidines

Stichwörter der Autor:innen

CD4+ T cellbaricitinibconcanavalin aimmune‐mediated liver injuryjanus kinase 2macrophages

Substanzen

Janus Kinase 2SulfonamidesAzetidinesbaricitinibPyrazolesPurinesJak2 protein, mouseBenzenesulfonamidesfedratinibConcanavalin A

Autor:innen und Institutionen

  • Division of Rheumatology and Immunology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Rheumatology and Immunology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • Sinopharm Dongfeng General Hospital (Hubei Clinical Research Center of Hypertension), Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, Hubei, China.
  • Fujian Institute of Clinical Immunology, Fuzhou, Fujian, China.
  • Department of Immunology, School of Medicine, Yangtze University, Jingzhou, Hubei, China.
  • Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Förderung

  • | Natural Science Foundation of Hubei Province ()
  • MOST | National Natural Science Foundation of China (NSFC)
  • MOST | National Key Research and Development Program of China (NKPs)
  • China Postdoctoral Science Foundation ()
  • Department of Science and Technology, Hubei Province | Science and Technology Program of Hubei Province ()
  • Natural Science Foundation of Hubei Province
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Li, X., Liu, X., Zhou, M., Yang, C., Chen, J., Lin, S., Gong, Q., Braunstein, Z., Wei, Y., Rao, X., & Zhong, J. (2026). Targeting JAK2 : Genetic and Pharmacological Inhibition Attenuates Immune‐Mediated Liver Injury by Suppressing Proinflammatory Macrophage. The FASEB Journal. https://doi.org/10.1096/fj.202504763rr

Vancouver

Li X, Liu X, Zhou M, Yang C, Chen J, Lin S, et al. Targeting JAK2 : Genetic and Pharmacological Inhibition Attenuates Immune‐Mediated Liver Injury by Suppressing Proinflammatory Macrophage. The FASEB Journal. 2026. doi:10.1096/fj.202504763rr

BibTeX
@article{Li2026,
  author = {Li, Xinlu and Liu, Xinxin and Zhou, Meijiang and Yang, Chenxi and Chen, Jun and Lin, Shunping and Gong, Quan and Braunstein, Zachary and Wei, Yingying and Rao, Xiaoquan and Zhong, Jixin},
  title = {Targeting JAK2 : Genetic and Pharmacological Inhibition Attenuates Immune‐Mediated Liver Injury by Suppressing Proinflammatory Macrophage},
  journal = {The FASEB Journal},
  year = {2026},
  doi = {10.1096/fj.202504763rr}
}
Kostenlos starten →